S&P 500   4,297.14
DOW   33,912.44
QQQ   333.06
The Five Hottest Calls From The Q2 Earnings Season 
Our Most Important Forecast in 50 Years Tectonic changes are on the way. (Ad)
Buffett's firm buys more Apple, Amazon while betting on oil
Norway hits export record amid soaring gas prices
Stocks end higher on Wall Street; economic worries hit oil
Our Most Important Forecast in 50 Years Tectonic changes are on the way. (Ad)
Myanmar executions revive pressure for more sanctions
Stocks higher on Wall Street; economic worries hit oil price
New climate deal spurs hopes of more carbon storage projects
Our Most Important Forecast in 50 Years Tectonic changes are on the way. (Ad)
S&P 500   4,297.14
DOW   33,912.44
QQQ   333.06
The Five Hottest Calls From The Q2 Earnings Season 
Our Most Important Forecast in 50 Years Tectonic changes are on the way. (Ad)
Buffett's firm buys more Apple, Amazon while betting on oil
Norway hits export record amid soaring gas prices
Stocks end higher on Wall Street; economic worries hit oil
Our Most Important Forecast in 50 Years Tectonic changes are on the way. (Ad)
Myanmar executions revive pressure for more sanctions
Stocks higher on Wall Street; economic worries hit oil price
New climate deal spurs hopes of more carbon storage projects
Our Most Important Forecast in 50 Years Tectonic changes are on the way. (Ad)
S&P 500   4,297.14
DOW   33,912.44
QQQ   333.06
The Five Hottest Calls From The Q2 Earnings Season 
Our Most Important Forecast in 50 Years Tectonic changes are on the way. (Ad)
Buffett's firm buys more Apple, Amazon while betting on oil
Norway hits export record amid soaring gas prices
Stocks end higher on Wall Street; economic worries hit oil
Our Most Important Forecast in 50 Years Tectonic changes are on the way. (Ad)
Myanmar executions revive pressure for more sanctions
Stocks higher on Wall Street; economic worries hit oil price
New climate deal spurs hopes of more carbon storage projects
Our Most Important Forecast in 50 Years Tectonic changes are on the way. (Ad)
S&P 500   4,297.14
DOW   33,912.44
QQQ   333.06
The Five Hottest Calls From The Q2 Earnings Season 
Our Most Important Forecast in 50 Years Tectonic changes are on the way. (Ad)
Buffett's firm buys more Apple, Amazon while betting on oil
Norway hits export record amid soaring gas prices
Stocks end higher on Wall Street; economic worries hit oil
Our Most Important Forecast in 50 Years Tectonic changes are on the way. (Ad)
Myanmar executions revive pressure for more sanctions
Stocks higher on Wall Street; economic worries hit oil price
New climate deal spurs hopes of more carbon storage projects
Our Most Important Forecast in 50 Years Tectonic changes are on the way. (Ad)
NASDAQ:BMRN

BioMarin Pharmaceutical - BMRN News Headlines

$96.94
+1.87 (+1.97%)
(As of 08/15/2022 12:00 AM ET)
Add
Compare
Today's Range
$94.48
$96.99
50-Day Range
$71.48
$96.00
52-Week Range
$70.73
$97.76
Volume
1.17 million shs
Average Volume
1.24 million shs
Market Capitalization
$17.98 billion
P/E Ratio
372.86
Dividend Yield
N/A
Price Target
$110.93
Get BioMarin Pharmaceutical News Delivered to You Automatically

Sign up to receive the latest news and ratings for BMRN and its competitors with MarketBeat's FREE daily newsletter.

BMRN Media Mentions By Week

BMRN Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

BMRN
News Sentiment

0.60

0.63

Average
Medical
News Sentiment

BMRN News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

BMRN Articles
This Week

17

5

BMRN Articles
Average Week



SourceHeadline
marketbeat.com logoBioMarin Pharmaceutical (NASDAQ:BMRN) Price Target Raised to $111.00
marketbeat.com - August 9 at 1:49 PM
MarketBeat logoBioMarin Pharmaceutical Inc. (NASDAQ:BMRN) EVP Charles Greg Guyer Sells 6,205 Shares
americanbankingnews.com - August 11 at 6:40 AM
MarketBeat logoBioMarin Pharmaceutical (NASDAQ:BMRN) PT Raised to $128.00 at Piper Sandler
americanbankingnews.com - August 11 at 3:08 AM
MarketBeat logoBioMarin Pharmaceutical (NASDAQ:BMRN) Given New $111.00 Price Target at Credit Suisse Group
americanbankingnews.com - August 10 at 7:46 AM
MarketBeat logoBioMarin Pharmaceutical (NASDAQ:BMRN) Upgraded to "Buy" at StockNews.com
americanbankingnews.com - August 10 at 4:52 AM
MarketBeat logoBioMarin Pharmaceutical (NASDAQ:BMRN) Given New $122.00 Price Target at SVB Leerink
americanbankingnews.com - August 8 at 6:16 AM
MarketBeat logoBioMarin Pharmaceutical Inc. to Post FY2022 Earnings of $1.10 Per Share, Cantor Fitzgerald Forecasts (NASDAQ:BMRN)
americanbankingnews.com - August 7 at 2:18 AM
MarketBeat logoBioMarin Pharmaceutical (NASDAQ:BMRN) PT Raised to $125.00 at Barclays
americanbankingnews.com - August 6 at 6:40 AM
MarketBeat logoBioMarin Pharmaceutical (NASDAQ:BMRN) PT Raised to $117.00
americanbankingnews.com - August 6 at 6:40 AM
nasdaq.com logoJune 2024 Options Now Available For BioMarin Pharmaceutical (BMRN)
nasdaq.com - August 5 at 4:03 PM
finance.yahoo.com logoBioMarin Lifts Annual Guidance On Better Than Expected Q2 Earnings
finance.yahoo.com - August 4 at 2:43 PM
finance.yahoo.com logoBioMarin's (BMRN) Q2 Earnings Top, Voxzogo Drives Sales
finance.yahoo.com - August 4 at 9:42 AM
seekingalpha.com logoBioMarin Pharmaceutical Inc. (BMRN) CEO J.J. Bienaime on Q2 2022 Results - Earnings Call Transcript
seekingalpha.com - August 4 at 1:21 AM
nasdaq.com logoBiomarin Pharmaceutical Inc. Bottom Line Rises In Q2, Beats estimates
nasdaq.com - August 3 at 8:21 PM
finance.yahoo.com logoBioMarin Announces Record Revenues in Second Quarter 2022; Increases Full-year 2022 Top and Bottom-line Guidance
finance.yahoo.com - August 3 at 8:21 PM
finance.yahoo.com logoBioMarin Pharmaceutical (BMRN) Q2 Earnings and Revenues Surpass Estimates
finance.yahoo.com - August 3 at 8:21 PM
MarketBeat logoStockNews.com Downgrades BioMarin Pharmaceutical (NASDAQ:BMRN) to Hold
americanbankingnews.com - August 3 at 2:38 AM
MarketBeat logoStockNews.com Lowers BioMarin Pharmaceutical (NASDAQ:BMRN) to Hold
americanbankingnews.com - August 3 at 2:38 AM
MarketBeat logoBioMarin Pharmaceutical (NASDAQ:BMRN) Rating Increased to Buy at StockNews.com
americanbankingnews.com - July 24 at 3:34 AM
MarketBeat logoBioMarin Pharmaceutical Inc. Expected to Post Q2 2022 Earnings of $0.25 Per Share (NASDAQ:BMRN)
americanbankingnews.com - July 23 at 1:52 AM
finance.yahoo.com logoBioMarin to Host Second Quarter 2022 Financial Results Conference Call and Webcast on Wednesday, August 3, at 4:30pm ET
finance.yahoo.com - July 20 at 2:41 PM
nasdaq.com logoFirst Week of BMRN September 16th Options Trading
nasdaq.com - July 16 at 10:52 PM
benzinga.com logoBioMarin Presents Findings from Studies of...
benzinga.com - July 13 at 10:21 AM
markets.businessinsider.com logoAnalyst Ratings for Biomarin Pharmaceutical
markets.businessinsider.com - July 13 at 10:21 AM
nasdaq.com logoBMRN June 2023 Options Begin Trading
nasdaq.com - July 11 at 7:28 PM
finance.yahoo.com logoBioMarin Presents Findings from Studies of Valoctocogene Roxaparvovec, Investigational Gene Therapy, at the International Society on Thrombosis and Haemostasis (ISTH) 2022 Congress July 9-12, Including 4 Oral and 2 Poster Presentations
finance.yahoo.com - July 11 at 7:28 PM
finance.yahoo.com logoPharma Rally Continues As Pfizer, Amgen Look To Break Out, Pulling Rivals With Them
finance.yahoo.com - July 11 at 7:28 PM
finance.yahoo.com logoStock Market Closes Lower; Nasdaq Leads Declines; This Biotech Is In Buy Zone
finance.yahoo.com - July 11 at 7:28 PM
seekingalpha.com logoBioMarin's Solid Pipeline Bears The First Fruit
seekingalpha.com - June 27 at 11:07 PM
finance.yahoo.com logoBioMarin (BMRN) Gets CHMP Nod for Hemophilia Drug Roctavian
finance.yahoo.com - June 27 at 6:06 PM
reuters.com logoUPDATE 2-BioMarin's haemophilia gene therapy set for European debut after regulatory nod
reuters.com - June 24 at 10:11 PM
seekingalpha.com logoBioMarin hemophilia gene therapy gets EMA panel backing for conditional approval in EU
seekingalpha.com - June 24 at 5:10 PM
nasdaq.com logoPositive CHMP Opinion For BioMarin's Gene Therapy To Treat Severe Hemophilia A
nasdaq.com - June 24 at 8:44 AM
finance.yahoo.com logoBioMarin Receives Positive CHMP Opinion in Europe for Valoctocogene Roxaparvovec Gene Therapy to Treat Adults with Severe Hemophilia A
finance.yahoo.com - June 24 at 8:44 AM
seekingalpha.com logoBioMarin Pharma gets Japan regulatory nod for Voxzogo to treat achondroplasia in children
seekingalpha.com - June 21 at 5:42 PM
finance.yahoo.com logoBioMarin Announces the Ministry of Health, Labor and Welfare (MHLW) in Japan Granted Approval for VOXZOGO® (vosoritide) for Injection for the Treatment of Children with Achondroplasia, Whose Growth Plates are Not Closed
finance.yahoo.com - June 21 at 5:42 PM
money.usnews.com logoBiomarin Pharmaceutical Inc. - Registered Shares
money.usnews.com - June 17 at 10:46 PM
nasdaq.com logoFirst Week of BMRN August 19th Options Trading
nasdaq.com - June 17 at 5:46 PM
seekingalpha.com logoBioMarin to seek labeling expansion for achondroplasia therapy after positive data
seekingalpha.com - June 13 at 3:56 PM
seekingalpha.com logoBioMarin initiated at neutral at Wedbush amid setback for hemophilia A candidate
seekingalpha.com - June 13 at 3:56 PM
finance.yahoo.com logoBioMarin Announces Favorable Results from Global Phase 2 Study of VOXZOGO™ (vosoritide) for Injection in Infants and Young Children with Achondroplasia at The Endocrine Society Annual Meeting, ENDO 2022 (June 11-14), in Atlanta
finance.yahoo.com - June 13 at 3:56 PM
finance.yahoo.com logoBioMarin delays refiling approval request for hemophilia gene therapy
finance.yahoo.com - May 31 at 8:33 PM
seekingalpha.com logoBioMarin says FDA seeks additional data on hemophilia A drug
seekingalpha.com - May 31 at 10:33 AM
finance.yahoo.com logoBioMarin Announces Durable Hemostatic Efficacy Maintained Over 6 years in Ongoing Phase 1/2 Study of Valoctocogene Roxaparvovec, Investigational Gene Therapy for Hemophilia A
finance.yahoo.com - May 31 at 10:32 AM
morningstar.com logoBiomarin Pharmaceutical Inc - Stock Valuation BMRN
morningstar.com - May 30 at 8:09 AM
finance.yahoo.com logoBioMarin (BMRN) Down 4.6% Since Last Earnings Report: Can It Rebound?
finance.yahoo.com - May 27 at 5:41 PM
finance.yahoo.com logoBioMarin (BMRN) Down 4.6% Since Last Earnings Report: Can It Rebound?
finance.yahoo.com - May 27 at 5:41 PM
seekingalpha.com logoBioMarin: A Good Anchor For Your Biotech Portfolio
seekingalpha.com - May 11 at 11:14 PM
finance.yahoo.com logoBioMarin Pharmaceutical (NASDAQ:BMRN shareholders incur further losses as stock declines 4.9% this week, taking five-year losses to 14%
finance.yahoo.com - May 11 at 12:59 PM
markets.businessinsider.com logoBioMarin Hires Pharmaceutical Industry Leaders in Marketing and Accounting to Fill Strategic Roles Supporting Company's Growth Plans
markets.businessinsider.com - May 5 at 6:47 PM
finance.yahoo.com logoBioMarin Hires Pharmaceutical Industry Leaders in Marketing and Accounting to Fill Strategic Roles Supporting Company's Growth Plans
finance.yahoo.com - May 5 at 6:47 PM
Get BioMarin Pharmaceutical News Delivered to You Automatically

Sign up to receive the latest news and ratings for BMRN and its competitors with MarketBeat's FREE daily newsletter.

This page (NASDAQ:BMRN) was last updated on 8/16/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.